Please login to the form below

Not currently logged in
Email:
Password:

Rydapt

This page shows the latest Rydapt news and features for those working in and with pharma, biotech and healthcare.

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

It is however the second drug in the class to be approved for marketing after Novartis’  Rydapt (midostaurin), which was cleared for newly-diagnosed FLT3-positive AML in the US and ... head study with Rydapt.

Latest news

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...